-
Ono Pharmaceutical Licenses Ionis’ Sapablursen for Global Development in Polycythemia Vera
•
Japan-based Ono Pharmaceutical Co., Ltd. (TYO: 4528) announced an agreement with Ionis Pharmaceuticals, Inc. to license sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Under the terms of the agreement, Ono has secured global development and commercialization rights to the drug. Terms of the AgreementOno will…
-
AstraZeneca’s Wainzua Earns CHMP Nod for hATTR-PN Treatment in the EU
•
UK pharmaceutical juggernaut AstraZeneca (AZ, NASDAQ: AZN) has announced that Wainzua (eplontersen), an RNA-targeted therapy co-developed with US-based Ionis Pharmaceuticals (NASDAQ: IONS), has received a positive recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) within the European Union (EU). The treatment is intended for adults…
-
Biogen Discontinues Aduhelm Development, Redirects Focus to Other Alzheimer’s Therapies
•
Biogen (NASDAQ: BIIB) has announced its decision to discontinue the development and commercialization of its Alzheimer’s disease (AD) drug Aduhelm (aducanumab), including a Phase IV post-marketing confirmatory study that was necessary to upgrade the treatment’s accelerated approval in the US. This move will incur USD 60 million in close-out costs…
-
AstraZeneca Secures FDA Approval for Self-Administered hATTR-PN Therapy Wainua
•
AstraZeneca (AZ, NASDAQ: AZN), headquartered in the UK, announced last week that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for its ligand-conjugated antisense oligonucleotide (LICA) Wainua (eplontersen) as a treatment for hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN/ATTRv-PN) in adults. Developed in collaboration with Ionis Pharmaceuticals (NASDAQ: IONS),…
-
Biogen’s BIIB080 Shows Promise in Phase Ib Trial for Mild Alzheimer’s Disease
•
Biogen (NASDAQ: BIIB) has released preliminary findings from a Phase Ib trial for BIIB080, a microtubule-associated protein tau (MAPT)-targeting antisense oligonucleotide (ASO) co-developed with Ionis Pharmaceuticals (NASDAQ: IONS). The trial focused on patients with mild Alzheimer’s disease (AD), showing that high doses of the spinal injection led to improvements in…
-
Roche Secures Global Rights to Ionis Pharmaceuticals’ Alzheimer’s and Huntington’s Disease Candidates
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced the acquisition of global rights to develop, manufacture, and commercialize two early-stage drug candidates for Alzheimer’s disease (AD) and Huntington’s disease (HD) from Ionis Pharmaceuticals (NASDAQ: IONS). This strategic move is set to bolster Roche’s pipeline in central nervous system (CNS) disorders…
-
Novartis AG and Ionis Pharmaceuticals Renew Collaboration on Lp(a)-Driven CVD Drug
•
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has returned to US-based Ionis Pharmaceuticals Inc., (NASDAQ: IONS) for a collaboration and license agreement aimed at the discovery, development, and commercialization of a novel drug for patients with lipoprotein(a) (Lp(a))-driven cardiovascular disease (CVD). Building on a Successful PartnershipNovartis and Ionis previously formed…
